论文部分内容阅读
As the development of nanotechnology, drug delivery systems have achieved accumulation at the tumor site by passive-targeting of EPR effect and active-targeting, it brought new alternative treatments for cancer therapy.While the therapeutic effects are far from perfect.It is on account of facts that nanocarriers might have difficulty in effective drug release.Pharmacological actvifies of the drug are attributed to the concentration of free drug and maintaining time at pharmacological target, so some pH-responsive nanocarriers like CSO-FBA-SA and redox-responsive nanocarriers such as CSO-ss-SA, A54-CSO-ss-SA and DOX-ss-CSO-SA were developed.Fast released drug was imaged in tumor cells as well as solid tumor in mice models and pH-or redox-responding of nanocarriers was revealed, which was verified by Nile red fluorescence marker.The method for determining the concentration of released free doxorubicin from micelles was established to expound time-dependent change of DOX-loaded micelles.The stimuli-responsive drug delivery systems showed a superior cytotoxicity in tumor cells on the basis of difference between the extra-and intra-cellular redox environments and pH environments.Low systemic toxicity was contributed to the difference behavior of carriers in normal and tumor tissues.The obtained glycolipid-like nanocarriers showed a passive tumor targeting ability, an efficient intra-tumor drug release property, and consequently a high tumor treating capacity.These results indicated that the drug release played an important role in the increase of the antitumor effect of the chitosan based glycolipid-like nanoparticles, and may suggest a new way of thinking about the accurate design of the nanocarriers.